Outset Medical Names Derick Elliott as Executive Vice President of Commercial
Rhea-AI Summary
Outset Medical (Nasdaq: OM) appointed Derick Elliott as Executive Vice President of Commercial, effective April 6, 2026. Elliott will lead commercial teams across acute, post-acute and home care and report to Chair and CEO Leslie Trigg. He brings 30+ years of sales and marketing experience from Stryker, Cardinal Health and SpendMend.
The company noted Elliott’s experience with capital equipment, software, EMR connectivity and recurring revenue and cited nearly 1,000 acute facilities using Tablo.
Positive
- Executive hire: Derick Elliott named EVP of Commercial, effective April 6, 2026
- Experience: Elliott brings 30+ years in sales and marketing
- Commercial focus: Background in capital equipment, software and recurring revenue
- Scale: Nearly 1,000 acute facilities using Tablo
Negative
- None.
News Market Reaction – OM
In the Apr 7 session, OM gained 0.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings results | Positive | -16.3% | Q4 and 2025 results with 5% revenue growth, margin expansion and guidance. |
| Jan 27 | Regulatory clearance | Positive | +14.3% | FDA 510(k) clearance for next‑generation Tablo hemodialysis platform with cybersecurity focus. |
| Jan 26 | Earnings date announcement | Neutral | +14.3% | Announcement of timing and webcast details for Q4 and full‑year 2025 results. |
| Jan 12 | Preliminary results | Positive | +22.1% | Unaudited 2025 revenue, improved cash use, Tablo adoption metrics and board change. |
| Jan 05 | Conference presentation | Positive | +12.9% | Planned presentation at J.P. Morgan Healthcare Conference with webcast access for investors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OM news has usually led to positive price reactions, though the latest earnings release on Feb 11, 2026 drew a negative response despite growth and guidance.
Over the past few months, OM has reported strengthening fundamentals and product milestones. Unaudited Q4 and 2025 results on Jan 12 showed revenue of $28.9M for Q4 and $119.5M for 2025, plus improved cash usage and more than 1,000 care sites using Tablo. FDA 510(k) clearance for the next‑generation Tablo platform arrived on Jan 27. Final earnings on Feb 11 confirmed these figures and introduced 2026 guidance, though shares fell 16.3% after that report.
Key Terms
emr connectivity technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately.
Mr. Elliott is responsible for Outset’s commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He joins Outset with more than 30 years of sales and marketing experience from Stryker, Cardinal Health and most recently SpendMend, a private company where he successfully drove a commercial strategy similar to Outset’s, leveraging a software, technology and services platform to change practice and help acute-care providers realize clinical, financial and operational benefits.
“Derick joins Outset at an ideal time as we expand our differentiated offering with new technology and services, and build on an already established base of clinical, operational and financial evidence to help acute and post-acute care providers realize the enormous benefits of insourcing dialysis with Outset and Tablo,” said Ms. Trigg. “He brings a strong track record of commercial strategy and execution across capital equipment, software, EMR connectivity and other recurring revenue streams, including partnering with health systems to create new service lines and optimize their operations. His broad and deep relationships with leading U.S. healthcare providers will serve us well as we continue to build on the nearly 1,000 acute facilities now using Tablo.”
Prior to joining Outset, Mr. Elliott served as Chief Commercial Officer of SpendMend. He previously served in sales and marketing roles of increasing responsibility for 17 years at Stryker, most recently as Vice President of Customer Solutions. Earlier in his career, he spent more than 10 years in sales and marketing roles in the Medical Products segment of Cardinal Health. He earned his MBA from the Kellogg School of Management at Northwestern University and Bachelor of Science degree in Business Administration with a concentration in finance from the University of Colorado Boulder.
“I have been impressed with the Outset management team, board and marquee roster of customers using Tablo to insource dialysis,” said Mr. Elliott. “This is a motivated team with a highly differentiated solution in one of the largest corners of healthcare. I am excited by the opportunity to help the company deliver the benefits of insourcing to an even broader set of customers and ultimately enable clinicians to improve the lives of the patients they serve.”
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.
Investor Contact
Jim Mazzola
jmazzola@outsetmedical.com
